There has been an uptick in licensing agreements for drugs incorporating clustered regularly interspaced short palindromic repeats (CRISPR)-based technology over the past five years, notes GlobalData.
The agreements, primarily concentrated in oncology, immunology, and central nervous system therapeutics, have collectively been worth $21 billion in deal value, the data and analytics company has found.
"CRISPR technology is transforming targeted gene therapies"From 2020 to 2022, there was a surge in deal worth, particularly in the domain of hematological disorders, reaching a substantial total deal value of $1.8 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze